[go: up one dir, main page]

MX2024010235A - Compuestos para su uso en el tratamiento de distrofinopatias. - Google Patents

Compuestos para su uso en el tratamiento de distrofinopatias.

Info

Publication number
MX2024010235A
MX2024010235A MX2024010235A MX2024010235A MX2024010235A MX 2024010235 A MX2024010235 A MX 2024010235A MX 2024010235 A MX2024010235 A MX 2024010235A MX 2024010235 A MX2024010235 A MX 2024010235A MX 2024010235 A MX2024010235 A MX 2024010235A
Authority
MX
Mexico
Prior art keywords
treatment
dystrophinopathy
prevention
compounds
dystrophinopathies
Prior art date
Application number
MX2024010235A
Other languages
English (en)
Inventor
Boronat Raúl Insa
Bolaño Núria Reig
Atsushi Asakura
Gambín Óscar Huertas
Mohr Gal La Pericot
Yoko Asakura
Del Olmo Marisol Montolio
Original Assignee
Som Innovation Biotech S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Som Innovation Biotech S A filed Critical Som Innovation Biotech S A
Publication of MX2024010235A publication Critical patent/MX2024010235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto seleccionado del grupo que consiste en difenpiramida, veliflapón, amopiroquina, cloricromeno, alpelisib, benorilato, xipamida, fabomotizol y altizida, o una sal farmacéuticamente aceptable de los mismos, y a combinaciones del mismo, para su uso en el tratamiento o la prevención de una distrofinopatía, al uso de los compuestos anteriormente mencionados para la preparación de un medicamento para el tratamiento o la prevención de una distrofinopatía y a métodos para el tratamiento o la prevención de una distrofinopatía en pacientes que lo necesitan mediante administración de los compuestos anteriormente mencionados.
MX2024010235A 2022-02-21 2023-02-20 Compuestos para su uso en el tratamiento de distrofinopatias. MX2024010235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22382147.1A EP4230196A1 (en) 2022-02-21 2022-02-21 Compounds for use in the treatment of dystrophinopathies
PCT/EP2023/054140 WO2023156645A1 (en) 2022-02-21 2023-02-20 Compounds for use in the treatment of dystrophinopathies

Publications (1)

Publication Number Publication Date
MX2024010235A true MX2024010235A (es) 2024-09-19

Family

ID=80446433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010235A MX2024010235A (es) 2022-02-21 2023-02-20 Compuestos para su uso en el tratamiento de distrofinopatias.

Country Status (10)

Country Link
US (1) US20250152567A1 (es)
EP (2) EP4230196A1 (es)
JP (1) JP2025508761A (es)
KR (1) KR20240150792A (es)
CN (1) CN118973560A (es)
AU (1) AU2023222467A1 (es)
CA (1) CA3244747A1 (es)
IL (1) IL315130A (es)
MX (1) MX2024010235A (es)
WO (1) WO2023156645A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025072685A1 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3111517A (en) 1959-01-06 1963-11-19 Pfizer & Co C Derivatives of 3, 4-dihydrobenzo-thiadiazine dioxides
BE637389A (es) 1962-09-13
GB1063821A (en) 1964-03-13 1967-03-30 Vsesoiuzny Ni Sky Khim Farmats Prednisone preparation
GB1101747A (en) 1964-04-09 1968-01-31 Sterwin Ag Salicylamide derivatives
DE1270544B (de) 1965-06-19 1968-06-20 Beiersdorf Ag 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung
GB1176266A (en) 1967-07-31 1970-01-01 Kyowa Hakko Kogyo Kk Process for Producing L-Citrulline
IT1044222B (it) 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
IT1088554B (it) 1977-11-17 1985-06-10 F I D I A Spa Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina
DE3069496D1 (de) 1979-06-28 1984-11-29 Takeda Chemical Industries Ltd 2,3-dialkoxy-1,4-quinone derivatives; method of producing 1,4-quinone derivatives
US4749649A (en) 1983-05-16 1988-06-07 The Upjohn Company Microbial Δ1-dehydrogenation process using a scavenger of toxic oxygen
DE3900261A1 (de) 1988-05-31 1989-12-07 Bayer Ag Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
US5332840A (en) 1993-05-27 1994-07-26 Bristol-Myers Squibb Company Method for preparing a benzaldehyde intermediate
US6376666B1 (en) 1994-06-10 2002-04-23 Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk 2-mercaptobenzimidazole derivatives possessing pharmacological activity
DE19529612A1 (de) 1995-08-11 1997-02-13 Merck Patent Gmbh Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate
ES2157476T3 (es) 1995-12-13 2001-08-16 Lepetit Spa Preparacion de (11beta,16beta)-21-(acetiloxi)-11-hidroxi-2'-metil-5'h-pregna-1,4-dien(17,16-d)oxazol-3,20-diona.
US5968826A (en) 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
ES2770035T3 (es) 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
EP2679237A1 (en) 2006-11-29 2014-01-01 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
DK2407466T3 (en) 2009-03-09 2016-03-07 Taiho Pharmaceutical Co Ltd Piperazine WHO IS ABLE TO INHIBIT prostaglandin D synthase
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
CN103282373B (zh) 2010-10-20 2016-06-08 泰国研究基金会 具有植物生长促进活性的脱皮素类似物
EP3296311B1 (en) 2010-11-18 2020-09-30 Technion Research & Development Foundation Ltd. Aminoglycosides and uses thereof in treating genetic disorders
CA3123992C (en) 2011-09-29 2024-06-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP2945643A4 (en) 2013-01-15 2017-04-26 Phasebio Pharmaceuticals, Inc. Therapeutic agents, compositions, and methods for glycemic control
WO2014115174A2 (en) 2013-01-26 2014-07-31 Sphaera Pharma Pvt. Ltd. Novel approach for synthesis of catechins
JP6461917B2 (ja) 2013-04-20 2019-01-30 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル エクソン２標的Ｕ７ｓｎＲＮＡポリヌクレオチド構築物の組換えアデノ随伴ウイルスによる送達
ZA201407536B (en) 2013-10-21 2017-09-27 Ems Sa Parenteral pharmaceutical composition containing cosyntropin
RS59764B1 (sr) 2014-06-17 2020-02-28 Nippon Shinyaku Co Ltd Antismisaona nukleinska kiselina za upotrebu u lečenju dišenove mišićne distrofije
EP2960336A1 (en) 2014-06-27 2015-12-30 Genethon Efficient systemic treatment of dystrophic muscle pathologies
WO2016059507A1 (en) 2014-10-13 2016-04-21 Kamavarapu Sarath Kumar Improved process for the preparation of high pure metformine
EP3350331A4 (en) 2015-09-17 2019-01-23 Research Institute at Nationwide Children's Hospital METHOD AND MATERIALS FOR GALGT2 GENE THERAPY
EA037371B1 (ru) 2015-10-07 2021-03-19 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
AU2017270598B2 (en) 2016-05-24 2022-12-01 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
EP3612191A4 (en) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCLE DYSTROPHY
TWI837102B (zh) 2017-10-17 2024-04-01 美商薩羅塔治療公司 用於反義遞送之細胞穿透肽
TWI844541B (zh) 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 寡核苷酸組成物及其使用方法
IT201900003281A1 (it) 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
KR20220107222A (ko) 2019-11-28 2022-08-02 리젠엑스바이오 인크. 마이크로디스트로핀 유전자 치료 작제물 및 이의 용도
WO2021231630A1 (en) 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases

Also Published As

Publication number Publication date
KR20240150792A (ko) 2024-10-16
CA3244747A1 (en) 2023-08-24
IL315130A (en) 2024-10-01
JP2025508761A (ja) 2025-04-10
CN118973560A (zh) 2024-11-15
AU2023222467A1 (en) 2024-09-26
WO2023156645A1 (en) 2023-08-24
EP4230196A1 (en) 2023-08-23
EP4482481B1 (en) 2025-11-12
US20250152567A1 (en) 2025-05-15
EP4482481A1 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
EP4353322A3 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX379425B (es) 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia.
MY199779A (en) Pyrrolopyrimidine compound and use thereof
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
MX2024014994A (es) Macrociclos de indazol y su uso
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
MX2024010235A (es) Compuestos para su uso en el tratamiento de distrofinopatias.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2025005392A (es) Composicion farmaceutica que comprende un inhibidor de aak1
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
AR108792A1 (es) Composiciones que comprenden timolol
AR134205A1 (es) Inhibidores de ripk1 y métodos de uso